July 30, 2025 a 01:01 pm
ABT: Analysts Ratings - Abbott Laboratories
Abbott Laboratories, a leading healthcare product provider, has a strong presence across pharmaceuticals, diagnostics, nutritionals, and medical devices. The company's robustness in innovation and market adaptation is reflected in its consistent buy ratings from analysts. However, the presence of strong sell recommendations indicates some market skepticism, potentially linked to broader sectoral challenges or competitive pressures. The stock remains a balanced opportunity with both growth potential and inherent risks.
Historical Stock Grades
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 7 | |
| Buy | 14 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
The sentiment surrounding Abbott Laboratories' stock has shown fluctuations over recent months. While strong buy ratings have remained relatively stable, there's a noteworthy increase in hold recommendations, indicating a more cautious approach by analysts.
- Overall analyst ratings have remained fairly consistent, with minor month-to-month variations.
- There is a decline in strong buy recommendations since the beginning of 2024, with increases in hold ratings.
- The stable number of buy ratings suggests sustained confidence in the company's core operations despite market uncertainties.
Percentage Trends
Analyzing the percentages, it is evident that there has been a shift in sentiment regarding Abbott Laboratories. The proportion of hold ratings has increased, signaling caution, while the percentage of buy ratings has remained stable. Such trends suggest a more conservative outlook among analysts.
- As of July 2025, 35% of analysts recommend a strong buy, a dip from the previous year.
- The number of hold recommendations has grown to represent 45% of all ratings.
- Strong sell ratings remain low, indicating that while there is caution, there is not widespread pessimism.
- Over the past 12 months, an increase in buy ratings was observed between October 2024 and July 2025, offsetting the decrease in holds.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-18 | Neutral | Neutral | Mizuho |
| 2025-07-18 | Buy | Hold | Jefferies |
| 2025-07-18 | Buy | Buy | BTIG |
| 2025-07-18 | Overweight | Overweight | Wells Fargo |
| 2025-07-18 | Outperform | Outperform | Raymond James |
Analyst Recommendations with Change of Opinion
Recent analyst activity indicates selective upgrades, suggesting an evolving confidence in Abbott Laboratories' strategic direction. Notably, certain analysts have shifted from hold to buy, which may reflect a positive reassessment of the company's prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-18 | Buy | Hold | Jefferies |
| 2023-07-21 | Peer Perform | Underperform | Wolfe Research |
| 2023-07-20 | Peer Perform | Underperform | Wolfe Research |
| 2021-10-27 | Overweight | Neutral | Atlantic Equities |
| 2021-10-26 | Overweight | Neutral | Atlantic Equities |
Interpretation
The analysis of Abbott Laboratories' ratings underscores a complex and evolving sentiment landscape. Analysts maintain a general confidence in the stock, given the predominance of buy recommendations. However, the growing proportion of hold ratings indicates recognition of potential risks or market saturation. The balance between buy and hold ratings suggests a cautious optimism. Importantly, the consistency in strong buy ratings reflects stable long-term confidence, though there is evidence of increasing scrutiny, potentially due to external market pressures.
Conclusion
In summary, Abbott Laboratories presents a robust investment opportunity balanced with inherent risks. Analysts express a mixed outlook, reflected in both stable buy recommendations and a rise in holds. Market confidence in Abbott's innovation and diversification across healthcare segments supports potential growth. Yet, concerns over competitive landscapes and broader economic conditions call for prudent monitoring. Overall, ABBT remains a pivotal player, with future prospects contingent upon strategic advancements and market dynamics.